哺乳动物雷帕霉素靶蛋白的表达及其与乳腺癌预后关系的Meta分析

doi:10.13481/j.1671-587x.20160428

吉林大学学报(医学版) ›› 2016, Vol. 42 ›› Issue (04): 783-788.doi: 10.13481/j.1671-587x.20160428

哺乳动物雷帕霉素靶蛋白的表达及其与乳腺癌预后关系的Meta分析

丁显飞¹, 周学良¹, 豆萌萌², 李砺锋¹, 郭丽娜³, 王峰¹, 樊青霞¹

1. 郑州大学第一附属医院肿瘤科, 河南郑州 450052;
2. 郑州大学第一附属医院中西医科, 河南郑州 450052;
3. 辽宁医学院护理学院, 辽宁锦州 121000

收稿日期:2016-01-12 发布日期:2016-07-20
通讯作者: 樊青霞,教授,博士研究生导师(Tel:0371-66295532,E-mail:fqx2243@126.com) E-mail:fqx2243@126.com
作者简介:丁显飞(1990-),男,河南省周口市人,在读医学硕士,主要从事食管癌基础和临床方面的研究。
基金资助:
河南省科技厅基础与前沿技术研究计划项目资助课题（132300410127）；河南省教育厅基础研究计划项目资助课题（13A320638）

Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis

DING Xianfei¹, ZHOU Xueliang¹, DOU Mengmeng², LI Lifeng¹, GUO Lina³, WANG Feng¹, FAN Qingxia¹

1. Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China;
2. Department of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China;
3. College of Nursing, Liaoning Medical University, Jinzhou 121000, China

Received:2016-01-12 Published:2016-07-20

摘要/Abstract

摘要：

目的：探讨哺乳动物雷帕霉素靶蛋白（mTOR）的表达及其与乳腺癌预后的关系，为mTOR抑制剂靶向治疗乳腺癌提供循证医学证据。方法：计算机检索PubMed、EMBase、Cochrane Library、ISI Web of Science和中国知网等数据库2015年12月24日之前的文献，收集mTOR表达与乳腺癌预后关系的研究，主要结局指标包含无病生存期（DFS）、总生存期（OS）；以风险比（HR）为效应量，各效应量以95%可信区间（CI）表示，采用STATA 12.0统计软件进行Meta分析。结果：纳入7项队列研究，共1758例患者。Meta分析，mTOR阳性表达乳腺癌患者发生复发和转移的风险是mTOR阴性表达患者的2.05倍（HR = 2.05，95% CI：1.01~4.13，P = 0.003）；mTOR阳性表达乳腺癌患者发生死亡的风险是mTOR阴性表达患者的2.63倍（HR = 2.63，95% CI：1.45~4.80，P = 0.736）。结论：mTOR表达阳性明显增加乳腺癌患者复发转移及死亡风险。

关键词: 乳腺肿瘤, 哺乳动物雷帕霉素靶蛋白, 预后, Meta分析

Abstract:

Objective: To explore the expression of mammalian target of rapamycin (mTOR) and its relationgship with the prognosis of breast cancer, and to provide evidence-based basis for the using of mTOR inhibitor in the treatment of breast cancer. Methods: A systemical literature search was conducted based on the following databases: PubMed, EMBbase, Cochrane Library, ISI Web of Science, and CNKI up to November 24, 2015. The outcome measures were hazard ratio (HR) with 95% confidence interval(CI)for the association between the mTOR expression and the prognosis of patients with breast cancer. The primary end points including disease-free survival (DFS), and overall survival (OS). STATA 12.0 was used to conduct the statistical analysis. Results: A total of seven cohort studies, 1 758 patients were included. The risk of recurrence and metastasis of the breast cancer patients with positive expression of mTOR was 2.05 times of the patients with negative expression of mTOR(HR=2.05,95%CI:1.01-4.13,P=0.003);the risk of death in the breast cancer patients with positive expression of mTOR was 2.63 times of the patients with negative expression of mTOR(HR=2.63,95%CI:1.45-4.80,P=0.736). Conclusion: The positive expression of mTOR can significantly increase the recurrence, metastasis and death risk of the patients with breast cancer.

Key words: breast neoplasms, mammalian target of rapamycin, prognosis, Meta-analysis

中图分类号:

R737.9

丁显飞, 周学良, 豆萌萌, 李砺锋, 郭丽娜, 王峰, 樊青霞. 哺乳动物雷帕霉素靶蛋白的表达及其与乳腺癌预后关系的Meta分析[J]. 吉林大学学报(医学版), 2016, 42(04): 783-788.

DING Xianfei, ZHOU Xueliang, DOU Mengmeng, LI Lifeng, GUO Lina, WANG Feng, FAN Qingxia. Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis[J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 783-788.

参考文献

[1] Parkin DM, Pisani P, Ferlay J, et al. Global cancer statistics[J]. CA Cancer J Clin, 1999, 49(1): 33-64.

[2] Sadeghi S, Olevsky O, Hurvitz SA. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine[J]. Pharmgenomics Pers Med, 2014, 7: 329-338.

[3] Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2002, 20(3): 719-726.

[4] Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk[J]. Nat Rev Mol Cell Biol, 2014, 15(3): 155-162.

[5] Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer[J]. Curr Opin Urol, 2013, 23(5): 472-478.

[6] Ng VC, Johnson JJ, Cuellar S. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer[J]. J Oncol Pharm Pract, 2015, 21(6): 433-442.

[7] Loong HH, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma[J]. Onco Targets Ther, 2014, 7: 575-585.

[8] Rolfo C, Giovannetti E, Hong DS, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors[J]. Cancer Treat Rev, 2014, 40(8): 990-1004.

[9] Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer[J]. J Natl Compr Canc Netw, 2013, 11(6): 670-678.

[10] Bakarakos P, Theohari I, Nomikos A, et al. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas[J]. Histopathology, 2010, 56(7): 876-882.

[11] Ueng SH, Chen SC, Chang YS, et al. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas[J]. Int J Clin Exp Pathol, 2012, 5(8): 806-813.

[12] Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Statist Med, 1998, 17(24): 2815-2834.

[13] Mei XD, Su H, Song J, et al. Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a Meta-analysis[J]. Biosci Trends, 2013, 7(1): 42-49.

[14] Qiu ZX, Zhang K, Qiu XS, et al. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis[J]. PLoS One, 2013, 8(12): e81451.

[15] An J, Jeong H, Lee Y, et al. Phosphorylated Akt and phosphorylated mTOR expression in breast invasive carcinomas: Analysis of 530 cases[J]. Breast Cancer, 2010, 13(4): 337.

[16] Bose S, Chandran S, Mirocha JM, et al. The Akt pathway in human breast cancer: A tissue-array-based analysis[J]. Mod Pathol, 2006, 19(2): 238-245.

[17] Ma BL, Shan MH, Sun G, et al. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer[J]. Mol Med Rep, 2015, 12(4): 5246-5254.

[18] 刘雅昕, 李惠平, 赵红梅, 等. mTOR表达与雌激素受体阳性乳腺癌辅助内分泌治疗预后的关系[J]. 癌症进展, 2013,11 (3): 254-258,269.

[19] 虞蕾楠, 姚广裕, 胡晓磊, 等. 雌激素受体阳性乳腺癌中mTOR蛋白的表达及与内分泌辅助治疗预后的关系[J]. 现代生物医学进展, 2015, 15(8): 1418-1420.

[20] Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison[J]. PLoS Negl Trop Dis, 2013, 7(5): e2195.

[21] Cai W, Shi Y, Zhao Q. Relationship between expression of mTOR and prognosis of early stage non-small cell lung cancer[J]. Zhonghua Zhong Liu Za Zhi, 2014, 36(2): 120-122.

[22] Leal P, Garcia P, Sandoval A, et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma[J]. Arch Pathol Lab Med, 2013, 137(4): 552-557.

[23] Xiao L, Wang YC, Li WS, et al. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray[J]. J Exp Clin Cancer Res, 2009, 28: 152.

[24] 俞媛,陈晓蓉.PI3K/Akt/mTOR信号转导道路在肝细胞癌发生发展中的作用[J].临床肝胆病杂志,2014,30(9):954-957.

[25] 叶荆, 王蓓, 陈建彬, 等. PI3K/Akt/mTOR通路抑制剂依维莫司治疗晚期乳腺癌的研究进展[J]. 肿瘤, 2015,35 (2): 221-224.

[26] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.

[27] Ito Y, Masuda N, Iwata H, et al. Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2 [J]. Gan To Kagaku Ryoho, 2015, 42(1): 67-75.

[28] André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Oncol, 2014,15(6): 580-591.

[29] 张莹,李春艳,崔泽实,等.TSG101与HIF-1α在乳腺癌组织中的表达及意义[J]. 中国实用内科杂志,2014,34(增1):96-98.

哺乳动物雷帕霉素靶蛋白的表达及其与乳腺癌预后关系的Meta分析

Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	漆璐, 白微, 于玮莹, 李媛媛, 华婉晴, 寇长贵. 沙格列汀联合胰岛素治疗2型糖尿病疗效随机对照试验的Meta分析[J]. 吉林大学学报(医学版), 2018, 44(06): 1235-1242.
[2]	于秀艳, 张晓伟, 丛占杰, 李铤, 吴雪峰. 乳腺癌患者血清中hMAM和CD147水平检测及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(06): 1269-1274.
[3]	朱广伟, 郑炜, 黄永建, 华进, 杨树钢, 叶建新. 髓样分化因子88在结直肠癌患者癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(05): 1047-1051.
[4]	郑芳, 欧阳征仁, 欧阳靖霖, 周诗力, 罗文. 乳腺癌患者超声图像特征与人类上皮生长因子受体2和Ki-67阳性表达的关联性分析[J]. 吉林大学学报(医学版), 2018, 44(05): 1073-1077.
[5]	朱涛, 张国明, 严飞, 刘正, 霍强. 急性心肌梗死患者PCI术后心率变异性对主要不良心脏事件的评估价值[J]. 吉林大学学报(医学版), 2018, 44(04): 780-785.
[6]	李晓, 邱香, 马振卉, 田亚萍. 皮肤转移癌伴发带状疱疹1例报告并文献复习[J]. 吉林大学学报(医学版), 2018, 44(04): 825-827.
[7]	马鸿云, 庄新明, 许维国, 刘一. 载阿霉素和顺铂的透明质酸纳米粒子对小鼠移植性乳腺癌的抑制作用[J]. 吉林大学学报(医学版), 2018, 44(02): 243-248.
[8]	于云鹤, 杜烨, 韩冰, 李嗣杰, 宋乐连, 范志民. 新辅助化疗对Luminal B型乳腺癌各亚组的疗效观察及预后分析[J]. 吉林大学学报(医学版), 2018, 44(02): 356-362.
[9]	范励雯, 付彤, 古林, 吴迪, 贾泓瑶, 宋东. 副乳腺癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 412-415.
[10]	高欢, 白元松, 代恩勇, 韩冷, 卢振霞, 赵亚男. 复发/难治性儿童B淋巴母细胞淋巴瘤1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 416-420.
[11]	何欣, 杨婷婷, 高阳阳, 宋艳秋. 乳腺癌患者心理韧性及其心理干预方式的研究进展[J]. 吉林大学学报(医学版), 2018, 44(02): 455-460.
[12]	李小霞, 孙艳, 曲荣锋, 任立参, 李亚荣. 原发性乳腺弥漫大B细胞性淋巴瘤3例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(01): 166-169.
[13]	齐亚莉, 刘扬, 梁硕, 龚守良, 王志成, 刘威武. 三重靶向介导的Smac过表达对乳腺癌MDA-MB-231细胞凋亡和周期进程的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 90-94.
[14]	马啸天, 岳小欣, 荣守华, 张玉超, 田远, 石瑛, 李君芳, 贾莉婷. miR-200c对三阴性乳腺癌上皮间质转化的抑制作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(01): 106-110.
[15]	高新雅, 张伟杰, 崔黎, 周学良, 马志俊, 吕转, 池艳艳, 王留兴. TM4SF1在乳腺癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2017, 43(06): 1186-1192.